Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta …
CS Padilha, PC Marinello, DA Galvao… - Journal of Cancer …, 2017 - Springer
Purpose Muscle atrophy and strength decline are two of the most prominent characteristics
in cancer patients undergoing cancer therapy, leading to decreased functional ability and …
in cancer patients undergoing cancer therapy, leading to decreased functional ability and …
Artificial intelligence to predict lymph node metastasis at CT in pancreatic ductal adenocarcinoma
Y Bian, Z Zheng, X Fang, H Jiang, M Zhu, J Yu, H Zhao… - Radiology, 2023 - pubs.rsna.org
Background Although deep learning has brought revolutionary changes in health care,
reliance on manually selected cross-sectional images and segmentation remain …
reliance on manually selected cross-sectional images and segmentation remain …
[HTML][HTML] Treatment of pancreatic cancer—neoadjuvant treatment in resectable pancreatic cancer (PDAC)
T Seufferlein, TJ Ettrich - Translational gastroenterology and …, 2019 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Curative-
intended resection and adjuvant chemotherapy represents the current standard of care …
intended resection and adjuvant chemotherapy represents the current standard of care …
Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma
Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials
The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …
Circulating tumor DNA as a clinical test in resected pancreatic cancer
Purpose: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-
specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform …
specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform …
FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …
A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic …
H Eguchi, Y Takeda, H Takahashi, S Nakahira… - Annals of surgical …, 2019 - Springer
Background Neoadjuvant therapy reportedly shows only marginal clinical benefit in
pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with …
pancreatic ductal adenocarcinoma (PDAC), especially in resectable cases. However, with …
S3-Leitlinie zum exokrinen pankreaskarzinom–langversion 2.0–dezember 2021–AWMF-registernummer: 032/010ol
T Seufferlein, J Mayerle, S Böck… - Zeitschrift für …, 2022 - thieme-connect.com
Familiäres Pankreaskarzinom (S. e836): Hier wird erstmals definiert, welchen Angehörigen
von Patienten mit familiärem Pankreaskarzinom welche genetischen Untersuchungen zur …
von Patienten mit familiärem Pankreaskarzinom welche genetischen Untersuchungen zur …
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy
Recent studies considered surgery as a treatment option for patients with pancreatic ductal
adenocarcinoma (PDAC) and synchronous liver metastases. The aim of this study was to …
adenocarcinoma (PDAC) and synchronous liver metastases. The aim of this study was to …